LAURA M KULIK
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
- Where
- Chesterton, IN
- NPI
- 1245262906
- Received
- $166,541 in 156 records, 2019 to 2025 ($163,023 general, $3,517 research)
- As principal investigator
- $398,015 of research payments to others in 6 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 17 | $9,938 |
| 2024 | General payment | 24 | $21,519 |
| 2023 | General payment | 29 | $40,854 |
| 2022 | General payment | 21 | $19,347 |
| 2021 | General payment | 19 | $19,179 |
| 2021 | Research payment | 2 | $3,517 |
| 2020 | General payment | 11 | $16,852 |
| 2019 | General payment | 33 | $35,331 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 44 | $53,968 | 2022–2025 |
| Exelixis Inc. | 28 | $32,548 | 2019–2023 |
| Eisai Inc. | 19 | $30,036 | 2019–2024 |
| Gilead Sciences, Inc. | 19 | $14,306 | 2019–2023 |
| Genentech, Inc. | 6 | $9,163 | 2019–2024 |
| AstraZeneca UK Limited | 4 | $8,860 | 2022–2023 |
| Genentech USA, Inc. | 8 | $5,527 | 2023–2024 |
| F. Hoffmann-La Roche AG | 3 | $5,267 | 2021 |
| FUJIFILM Healthcare Americas Corporation | 7 | $3,373 | 2021–2024 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $1,920 | 2021 |
| ABBVIE INC. | 1 | $625 | 2020 |
| Novo Nordisk Inc | 8 | $500 | 2023–2025 |
| Sirtex Medical Inc | 2 | $396 | 2025 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 | 2023 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 | 2022 |
| FUJIFILM Wako Diagnostics U.S.A. Corporation | 1 | $12 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 37 | $79,400 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 34 | $71,546 |
| Travel and Lodging | 20 | $6,430 |
| Food and Beverage | 61 | $5,606 |
| Research payment | 2 | $3,517 |
| Education | 2 | $40 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-12 | AstraZeneca Pharmaceuticals LP | $537 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-12-10 | Sirtex Medical Inc | $253 | Food and Beverage | Cash or cash equivalent | SIR-Spheres Microspheres Device, Interventional Oncology | 2025 | |
| 2025-10-07 | Sirtex Medical Inc | $142 | Food and Beverage | Cash or cash equivalent | SIR-Spheres Microspheres Device, Interventional Oncology | 2025 | |
| 2025-10-03 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-09-22 | AstraZeneca Pharmaceuticals LP | $2,148 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $131 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-12 | AstraZeneca Pharmaceuticals LP | $268 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-08-11 | AstraZeneca Pharmaceuticals LP | $2,148 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-13 | Novo Nordisk Inc | $32 | Education | In-kind items and services | Drug | 2025 | |
| 2025-06-10 | Novo Nordisk Inc | $118 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-10 | Novo Nordisk Inc | $64 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-04 | AstraZeneca Pharmaceuticals LP | $123 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-08 | AstraZeneca Pharmaceuticals LP | $537 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-30 | AstraZeneca Pharmaceuticals LP | $95 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-03 | AstraZeneca Pharmaceuticals LP | $1,074 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-11 | AstraZeneca Pharmaceuticals LP | $2,148 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-02-04 | AstraZeneca Pharmaceuticals LP | $99 | Food and Beverage | In-kind items and services | 2025 | ||
| 2024-12-22 | AstraZeneca Pharmaceuticals LP | $537 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-12-19 | AstraZeneca Pharmaceuticals LP | $28 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-26 | AstraZeneca Pharmaceuticals LP | $4,225 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-18 | AstraZeneca Pharmaceuticals LP | $134 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-11-16 | Genentech, Inc. | $127 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-15 | AstraZeneca Pharmaceuticals LP | $55 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-24 | AstraZeneca Pharmaceuticals LP | $537 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-15 | Novo Nordisk Inc | $89 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-15 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-02 | Eisai Inc. | $3,465 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2024 | |
| 2024-08-12 | AstraZeneca Pharmaceuticals LP | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-07-17 | AstraZeneca Pharmaceuticals LP | $2,685 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-26 | Eisai Inc. | $2,580 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2024 | |
| 2024-04-26 | Novo Nordisk Inc | $99 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-17 | FUJIFILM Healthcare Americas Corporation | $118 | Food and Beverage | In-kind items and services | UTASWAKO AFP-L3 Device, Medical Device | 2024 | |
| 2024-03-19 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-03-15 | AstraZeneca Pharmaceuticals LP | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-03-14 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-03-13 | AstraZeneca Pharmaceuticals LP | $36 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-02-09 | Genentech USA, Inc. | $243 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-02-09 | Genentech USA, Inc. | $139 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-02-09 | Genentech USA, Inc. | $138 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-02-09 | Genentech USA, Inc. | $81 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-02-08 | AstraZeneca Pharmaceuticals LP | $110 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2023-12-18 | AstraZeneca Pharmaceuticals LP | $2,148 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-12 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-12-06 | AstraZeneca Pharmaceuticals LP | $115 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2023 | |
| 2023-10-27 | AstraZeneca UK Limited | $1,611 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-10-20 | AstraZeneca UK Limited | $4,833 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-21 | AstraZeneca Pharmaceuticals LP | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-09-20 | Intercept Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | OCALIVA Drug, Hepatology / Gastroenterology | 2023 | |
| 2023-09-14 | AstraZeneca Pharmaceuticals LP | $537 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-24 | Exelixis Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2023 | |
| 2023-07-26 | AstraZeneca Pharmaceuticals LP | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-07-13 | AstraZeneca Pharmaceuticals LP | $76 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2023 | |
| 2023-06-27 | AstraZeneca Pharmaceuticals LP | $4,296 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-03 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-16 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-04-06 | AstraZeneca Pharmaceuticals LP | $7,786 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-03-24 | Gilead Sciences, Inc. | $27 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-03-06 | AstraZeneca Pharmaceuticals LP | $1,879 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-02-28 | Exelixis Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2023 | |
| 2023-02-25 | AstraZeneca Pharmaceuticals LP | $81 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2023 | |
| 2023-02-25 | AstraZeneca Pharmaceuticals LP | $27 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-02-23 | Genentech USA, Inc. | $4,625 | Consulting Fee | Cash or cash equivalent | Tecentriq Biological, BioOncology | 2023 | |
| 2023-02-23 | Genentech USA, Inc. | $131 | Food and Beverage | In-kind items and services | Tecentriq Biological, BioOncology | 2023 | |
| 2023-02-23 | Genentech USA, Inc. | $56 | Food and Beverage | In-kind items and services | Tecentriq Biological, BioOncology | 2023 | |
| 2023-02-22 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-02-16 | Novo Nordisk Inc | $64 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-02-06 | AstraZeneca Pharmaceuticals LP | $298 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-02-06 | AstraZeneca Pharmaceuticals LP | $167 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-01-24 | AstraZeneca UK Limited | $1,342 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-01-20 | Genentech USA, Inc. | $110 | Food and Beverage | In-kind items and services | 2023 | ||
| 2022-12-01 | AstraZeneca Pharmaceuticals LP | $4,296 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2022 | |
| 2022-12-01 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2022 | |
| 2022-11-22 | Exelixis Inc. | $5,920 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-11-17 | FUJIFILM Healthcare Americas Corporation | $1,473 | Consulting Fee | Cash or cash equivalent | UTASWAKO AFP-L3 Device, Medical Device | 2022 | |
| 2022-11-17 | FUJIFILM Healthcare Americas Corporation | $212 | Food and Beverage | In-kind items and services | UTASWAKO AFP-L3 Device, Medical Device | 2022 | |
| 2022-11-06 | AstraZeneca Pharmaceuticals LP | $120 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-11-05 | FUJIFILM Healthcare Americas Corporation | $212 | Food and Beverage | In-kind items and services | UTASWAKO AFP-L3 Device, Medical Device | 2022 | |
| 2022-10-28 | Exelixis Inc. | $371 | Travel and Lodging | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-10-28 | Exelixis Inc. | $106 | Travel and Lodging | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-10-28 | Exelixis Inc. | $100 | Food and Beverage | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-10-28 | Exelixis Inc. | $50 | Food and Beverage | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-10-28 | Exelixis Inc. | $39 | Travel and Lodging | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-10-27 | Exelixis Inc. | $486 | Travel and Lodging | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-10-27 | Exelixis Inc. | $239 | Travel and Lodging | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-10-27 | Exelixis Inc. | $126 | Food and Beverage | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-10-27 | Exelixis Inc. | $65 | Travel and Lodging | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-07-15 | AstraZeneca Pharmaceuticals LP | $6 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-05-13 | Exelixis Inc. | $740 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-05-06 | Eisai Inc. | $2,580 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2022 | |
| 2022-02-25 | Exelixis Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-01-11 | AstraZeneca UK Limited | $1,074 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2021-12-21 | Exelixis Inc. | $3,330 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2021 | |
| 2021-12-16 | Exelixis Inc. | $2,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2021 | |
| 2021-11-18 | Eisai Inc. | $2,580 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2021 | |
| 2021-08-18 | F. Hoffmann-La Roche AG | $2,497 | Research payment | In-kind items and services | TECENTRIQ Biological, BioOncology | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZ | 2021 |
| 2021-08-13 | Gilead Sciences, Inc. | $8 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-07-30 | Eisai Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Lenvima Drug, Oncology | 2021 | |
| 2021-07-12 | Eisai Inc. | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Lenvima Drug, Oncology | 2021 | |
| 2021-07-12 | Eisai Inc. | $118 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2021 | |
| 2021-07-01 | Gilead Sciences, Inc. | $21 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-06-17 | Eisai Inc. | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Lenvima Drug, Oncology | 2021 | |
| 2021-05-21 | FUJIFILM Healthcare Americas Corporation | $215 | Food and Beverage | In-kind items and services | Synapse 3D Device, Medical Device | 2021 | |
| 2021-05-20 | FUJIFILM Healthcare Americas Corporation | $1,125 | Consulting Fee | Cash or cash equivalent | uTASWako AFP-L3 Device, Medical Device | 2021 | |
| 2021-05-20 | Bayer Healthcare Pharmaceuticals Inc. | $640 | Consulting Fee | Cash or cash equivalent | Nexavar Drug, Oncology | 2021 | |
| 2021-05-20 | Bayer Healthcare Pharmaceuticals Inc. | $640 | Consulting Fee | Cash or cash equivalent | Nexavar Drug, Oncology | 2021 | |
| 2021-05-19 | F. Hoffmann-La Roche AG | $1,020 | Research payment | In-kind items and services | TECENTRIQ Biological, BioOncology | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZ | 2021 |
| 2021-05-03 | F. Hoffmann-La Roche AG | $1,750 | Consulting Fee | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | 2021 | |
| 2021-04-25 | FUJIFILM Healthcare Americas Corporation | $15 | Food and Beverage | In-kind items and services | Synapse 3D Device, Medical Device | 2021 | |
| 2021-03-15 | Gilead Sciences, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2021 | |
| 2021-01-21 | Bayer Healthcare Pharmaceuticals Inc. | $320 | Consulting Fee | Cash or cash equivalent | Nexavar Drug, Oncology | 2021 | |
| 2021-01-21 | Bayer Healthcare Pharmaceuticals Inc. | $320 | Consulting Fee | Cash or cash equivalent | Nexavar Drug, Oncology | 2021 | |
| 2021-01-20 | Eisai Inc. | $1,575 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2021 | |
| 2020-12-14 | Gilead Sciences, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2020 | |
| 2020-12-11 | Eisai Inc. | $630 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Lenvima Drug, Oncology | 2020 | |
| 2020-12-10 | Genentech, Inc. | $2,080 | Consulting Fee | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | 2020 | |
| 2020-11-30 | Exelixis Inc. | $3,330 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabometyx Drug, Oncology | 2020 | |
| 2020-10-05 | Gilead Sciences, Inc. | $1,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2020 | |
| 2020-09-02 | ABBVIE INC. | $625 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-08-13 | Exelixis Inc. | $2,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabometyx Drug, Oncology | 2020 | |
| 2020-08-13 | Exelixis Inc. | $1,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabometyx Drug, Oncology | 2020 | |
| 2020-06-11 | Eisai Inc. | $3,465 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2020 | |
| 2020-03-03 | Exelixis Inc. | $567 | Travel and Lodging | In-kind items and services | 2020 | ||
| 2020-02-28 | Eisai Inc. | $34 | Food and Beverage | Cash or cash equivalent | 2020 | ||
| 2019-12-06 | Genentech, Inc. | $324 | Food and Beverage | In-kind items and services | Avastin Biological, BioOncology | 2019 | |
| 2019-12-05 | Genentech, Inc. | $5,315 | Consulting Fee | Cash or cash equivalent | Avastin Biological, BioOncology | 2019 | |
| 2019-12-05 | Genentech, Inc. | $725 | Travel and Lodging | In-kind items and services | Avastin Biological, BioOncology | 2019 | |
| 2019-12-05 | Genentech, Inc. | $591 | Travel and Lodging | In-kind items and services | Avastin Biological, BioOncology | 2019 | |
| 2019-11-10 | Eisai Inc. | $1,890 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-11-10 | Eisai Inc. | $93 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-11-10 | FUJIFILM Wako Diagnostics U.S.A. Corporation | $12 | Food and Beverage | In-kind items and services | Wako HCC Biomarker(s) DCP and AFP-L3 Device, In Vitro Diagnostics | 2019 | |
| 2019-10-07 | Gilead Sciences, Inc. | $3,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2019 | |
| 2019-09-30 | Gilead Sciences, Inc. | $119 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2019 | |
| 2019-09-19 | Gilead Sciences, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2019 | |
| 2019-08-15 | Eisai Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-08-15 | Eisai Inc. | $77 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-08-08 | Eisai Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-08-08 | Eisai Inc. | $117 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-08-05 | Exelixis Inc. | $651 | Travel and Lodging | In-kind items and services | Cabometyx Drug, Oncology | 2019 | |
| 2019-07-26 | Gilead Sciences, Inc. | $3,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-07-24 | Gilead Sciences, Inc. | $124 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-07-12 | Exelixis Inc. | $5,920 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabometyx Drug, Oncology | 2019 | |
| 2019-07-12 | Exelixis Inc. | $312 | Travel and Lodging | In-kind items and services | Cabometyx Drug, Oncology | 2019 | |
| 2019-07-12 | Exelixis Inc. | $114 | Food and Beverage | In-kind items and services | Cabometyx Drug, Oncology | 2019 | |
| 2019-07-12 | Exelixis Inc. | $83 | Travel and Lodging | In-kind items and services | Cabometyx Drug, Oncology | 2019 | |
| 2019-07-12 | Exelixis Inc. | $64 | Food and Beverage | In-kind items and services | Cabometyx Drug, Oncology | 2019 | |
| 2019-07-11 | Exelixis Inc. | $170 | Food and Beverage | In-kind items and services | Cabometyx Drug, Oncology | 2019 | |
| 2019-06-13 | Gilead Sciences, Inc. | $62 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-04-09 | Eisai Inc. | $630 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-04-05 | Gilead Sciences, Inc. | $56 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2019 | |
| 2019-03-21 | Exelixis Inc. | $8 | Education | In-kind items and services | 2019 | ||
| 2019-03-09 | Gilead Sciences, Inc. | $3,720 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2019 | |
| 2019-03-09 | Gilead Sciences, Inc. | $906 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2019 | |
| 2019-03-09 | Gilead Sciences, Inc. | $196 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2019 | |
| 2019-03-09 | Gilead Sciences, Inc. | $182 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2019 | |
| 2019-03-09 | Gilead Sciences, Inc. | $50 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2019 | |
| 2019-03-09 | Gilead Sciences, Inc. | $50 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2023-03-01 | Bayer Healthcare Pharmaceuticals Inc. | Northwestern Memorial Healthcare | $1,500 | REFINE | 2023 |
| 2023-03-01 | Bayer Healthcare Pharmaceuticals Inc. | Northwestern Memorial Healthcare | $2,600 | REFINE | 2023 |
| 2023-03-01 | Bayer Healthcare Pharmaceuticals Inc. | Northwestern Memorial Healthcare | $1,950 | REFINE | 2023 |
| 2023-03-01 | Bayer Healthcare Pharmaceuticals Inc. | Northwestern Memorial Healthcare | $1,950 | REFINE | 2023 |
| 2022-04-27 | E.R. Squibb & Sons, L.L.C. | Northwestern University | $66,080 | 2017-NIV-0855 The combination of radioembolization w/ Nivolumab in Pts w/ unresectable advanced HCC | 2022 |
| 2021-10-21 | Boston Scientific Corporation | Northwestern University | $323,935 | TS-103 STOP-HCC | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Chesterton, IN, county Porter County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Chesterton, IN | County Porter County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 14,446 | 174,818 | 6,851,073 |
| Population, 2020 census P1 | 14,241 | 173,215 | 6,785,528 |
| Median age B01002 | 38.4 | 40.8 | 38.1 |
| Under 18 B01001 | 24.5% | 21.3% | 23.3% |
| 65 and over B01001 | 17.6% | 18.3% | 16.8% |
| Households B11001 | 6,004 | 68,639 | 2,716,009 |
| Foreign born B05002 | 4.3% | 4.0% | 6.3% |
| Median household income B19013 | $91,060 | $87,972 | $71,957 |
| Median family income B19113 | $114,545 | $105,644 | $90,767 |
| Per capita income B19301 | $50,086 | $44,216 | $38,351 |
| Poverty rate B17001 | 9.3% | 9.6% | 12.3% |
| Unemployment rate B23025 | 6.7% | 4.7% | 4.3% |
| Civilian labor force B23025 | 7,807 | 89,358 | 3,472,016 |
| Mean commute (minutes) B08013 | 25.6 | 28.4 | 24.1 |
| Bachelor's degree or higher B15003 | 42.5% | 31.1% | 29.5% |
| Housing units B25001 | 6,317 | 72,662 | 2,976,568 |
| Owner-occupied B25003 | 75.1% | 77.7% | 70.6% |
| Renters B25003 | 24.9% | 22.3% | 29.4% |
| Median home value B25077 | $300,900 | $281,500 | $218,200 |
| Median gross rent B25064 | $1,274 | $1,219 | $1,062 |
| White, not Hispanic B03002 | 86.2% | 79.1% | 75.4% |
| Black B03002 | 1.7% | 4.3% | 9.1% |
| Hispanic or Latino B03002 | 6.2% | 11.7% | 8.6% |
| Asian B03002 | 1.9% | 1.4% | 2.6% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Chesterton, IN.
Comments